Pharma

By Laura Lovett June 8, 2018
The road to digital innovation in the pharma and healthcare space is going to take players across industries — from tech developers and engineers to researchers and clinicians, according to a panel of digital-focused VPs speaking at BIO 2018 in Boston.  Tech is opening up new avenues in research and development, as well as access to data from EHRs and other databases. In the past, the healthcare...

Dr. Daniel Karlin, Greg Plante, Dr. Stephen Wicks, Dr. Zachary Beattie, and Dr. Mahesh Fuldeore

By Jonah Comstock June 8, 2018
Pharma companies are increasingly embracing the use of wearables and other connected devices to streamline and improve data collection in clinical trials. But for all the advantages these devices might have, there also challenges — especially when it comes to data standardization. This week at BIO 2018, Dr. Daniel Karlin, Pfizer’s head of clinical, informatics, regulatory strategy, digital...
By Dave Muoio June 8, 2018
Digital technologies are cementing their place across healthcare, and the pharmaceutical sector is no exception. This week Boston was host to the Biotechnology Innovation Organization’s annual conference, a multi-day gathering of leading pharma and biotech leaders from across the globe. While, admittedly, digital health wasn’t always the primary interest of many attendees and speakers, it was...
By Laura Lovett June 7, 2018
A drug no longer needs to be a tangible object, according to panelist at the BIO 2018 convention in Boston. The way the pharma industry looks at medication is evolving and may be including new tech-focused treatments, such as digital therapeutics. “If you think about the trajectory of medicine what is a drug these days: is it a pill, is it an injection, is it infusion, is it gene therapy? We’ve...
By Dave Muoio June 6, 2018
Stakeholders across healthcare are beginning to weigh the benefits and challenges digital therapeutics could bring to their businesses, and pharma is no exception. During an afternoon roundtable session held Wednesday at BIO 2018 in Boston, a panel of digital medicine and pharmaceutical representatives discussed the impact that these novel medicines has had, and could have, on drugmakers,...
Former Apple CEO John Sculley speaks with Wainwright Fishburn, of Cooley LLP during the BIO18 event on Wednesday.

Former Apple CEO John Sculley speaks with Wainwright Fishburn, of Cooley LLP during the BIO18 event on Wednesday.

By Dave Muoio June 6, 2018
When it comes to the challenges of raising an up-and-coming young company into a major player in its industry, former Apple and Pepsi CEO John Sculley is no spring chicken. A serial entrepreneur and investor across numerous industries ranging from consumer technology to data management to telecommunications, Sculley has set his sights on the healthcare and currently serves as the chairman of...
By Laura Lovett May 24, 2018
This week Blink Health, which makes an app and online tool for helping consumers find low prices for medications, filed a new legal claim against former partner MedImpact Healthcare System alleging greed and misconduct while describing the company as a “peddler of opioids.”  This claim comes as a second amendment to another ongoing lawsuit between the two companies, which seeks a trial by jury...
By Jonah Comstock May 22, 2018
Specialty pharmaceuticals are all different, but there’s one thing they have in common: they are difficult to prescribe. Whether it’s because of high cost, high risk, narrow therapeutic range, or complicated dosing, these drugs require would-be prescribing physicians to prove to insurers the drug is the right choice for their patient by filling out a number of forms and providing key data about...
By Jonah Comstock May 17, 2018
Sanofi’s approach to digital health is broad, but focused, Rachel Sha, the company’s vice president of digital business development and licensing, told MobiHealthNews in an interview ahead of the upcoming BIO 2018 conference in Boston, where Sha will be speaking on a range of digital health-related topics. “At Sanofi we’re lucky in the sense that we have a very clear set of digital priorities...
By Jonah Comstock May 16, 2018
Cambridge, Massachusetts-based sensor maker MC10, known for its flexible and stretchable electronics, has received its first FDA 510(k) clearance for the BioStamp nPoint system. BioStamp nPoint is a more advanced version of the company's non-FDA cleared BioStampRC. "BiostampRC was primarily developed as an investigational tool, primarily used by academia, as well as by pharmaceutical companies,...